|
Recently Completed Clinical Trials
This section highlights recently completed clinical trials. Dermatology
Emergency and Critical Care
Large Animal Medicine and Surgery
Neurology
Oncology
Small Animal Medicine
Small Animal Surgery
Dermatology Ceramide composition of the stratum corneum of canine patients with dermatitis. Principal Investigators:
Sheila M. F. Torres, DVM, MS, PhD, DACVD
Lisa Reiter, DVM
Contact:
Dr. Reiter - E-mail reite052@umn.edu
Dr. Torres - Phone: 612-624-3746 - E-mail torre009@umn.edu This study looked at the composition of the skin of dogs with allergies and is pending publication. Return to top
Emergency and Critical Care High Mobility Group B-1 Protein as a Diagnostic and Prognostic Tool in Canine Systemic Inflammatory Response Syndrome and Sepsis Principal Investigator: Kelly Hall, DVM
Contact: Dr. Kelly Hall, Phone: 612-624-6288 E-mail: wilke022@umn.edu HMGB-1 is known to be involved in inflammatory processes in other mammal species (e.g., humans, mice). HMGB-1 has been identified as a protein in inflammatory processes, including sepsis, arthritis and cancer. This study evaluated whether HMGB-1 can be detected in normal canine patient serum and if it changes significantly in known inflammatory processes (e.g., sepsis) or other naturally occurring animal diseases. Return to top
Large Animal Medicine and Surgery Aldara use in Equines. See this page for FAQs and Veterinarian Instructions for use of Aldara (imiquimod). Treatment of Aural Plaques with 5% Imiquimod Cream: an Open Label Clinical Trial. This study evaluated the use of Aldara (imiquimod) for the treatment of aural plaques in horses. Efficacy of Aldara (Imiquimod) on the Treatment of Equine Sarcoids. This study investigated the effectiveness of Aldara on equine sarcoids. Return to top Neurology Neuropathic pain in Cavalier King Charles Spaniels Principal Investigator: Ned Patterson, DVM, PhD, DACVIM
Contact: Dr. Patterson, 612-625-5799, e-mail: patte037@umn.edu The Clinical Investigation Center has completed a clinical study evaluating the efficacy of a novel treatment for the control of pain associated with syringomyelia in Cavalier King Charles Spaniels. The study was part of a collaborative effort between a Pharmaceutical Company, and the Schools of Veterinary Medicine at the University of Minnesota, the University of Pennsylvania and the Royal Veterinary College in the United Kingdom. The study actively recruited patients from November 2007 to October 2008 and after screening 119 dogs, a total of fifty two patients participated in the trial.
Following statistical analysis, the results are promising. There is potential for further development of this new medication to help alleviate the pain associated with syringomyelia. Return to top
Oncology Phase I Lymphoma study in large dogs Principal Investigator: Brian Husbands, DVM
Contact: Dr. Husbands, 612-625-6722, E-mail: husba002@umn.edu The last dogs have been enrolled in a multi-institutional clinical trial of a new chemotherapeutic medication to treat lymphoma. Results are pending. A pilot study to evaluate dynamic contrast-enhancement MRI characteristics of canine malignant and benign pulmonary nodules
Principal Investigator: Vicki Wilke, DVM, PhD, DACVS
Contact: Dr. Vicki Wilke, E-mail: wilke175@umn.edu
Dogs with a lung mass, masses or focal lung infiltrate (cancer, infectious, or benign) were examined by magnetic resonance imaging (MRI). Results are pending. Return to top
Small Animal Medicine Diagnosis of Clinical Acute Canine Pancreatitis using a new assay Principal Investigator: Jane Armstrong DVM, PhD
Contact: Dr. Jane Armstrong, 612-625-5799 E-mail: armst002@umn.edu
This multi-site study examined the diagnostic usefulness (sensitivity and specificity) of the pancreatic lipase blood test. Two groups of dogs were compared: those which might have pancreatitis and those with unrelated problems (control dogs). Results from the 60 control dogs enrolled at the Veterinary Medical Center will be evaluated with results from approximately 75 dogs presented for signs consistent with pancreatitis seen by veterinary internists across the country. Preliminary results from the study were submitted as an abstract for the ACVIM Forum in Montreal, Canada in June 2009. Return to top
Small Animal Surgery
Provoking anti tumor immune responses with FAS ligand Principal Investigator: Vicki Wilke, DVM, PhD, DACVS
Contact: Dr. Vicki Wilke: 612-625-4966 E-mail: wilke175@umn.edu
This study treated dogs with untreated Stage I or II osteosarcoma with a new gene therapy, followed by standard of care amputation and chemotherapy. The particular gene therapy referred to as Fasaret® has demonstrated anti-tumor responses in rodents as well as in canine oral melanoma. Fasaret therapy given to canine patients with other tumor types has not resulted in any systemic side effects when administered directly into the tumor or other tissues. The gene is carried to the tumor cells by an adenovirus vector. This virus vector cannot replicate on its own and carries no risk itself to humans or animals that might come into contact with it. What was involved - Diagnostic tests and x-rays, all part of normal staging for canine patients with osteosarcoma
- Bone biopsy and treatment with Fasaret directly into the tumor
- Amputation 10 days after the Fasaret was administered
- Chemotherapy started two weeks after amputation, four visits at three weeks apart plus recheck visits in between, blood and urine collected at each recheck visit
- Following chemotherapy, recheck visits every three months
Results are pending. Return to top
|
